AgomAb Therapeutics NV (Nasdaq: AGMB) is a six-month-old public company whose first year as a listed equity has been defined by the upcoming initiation of the first-ever Phase 2b trial in fibrostenosing Crohn's disease. The first half of 2026 closed on August 6, 2026 with the company confirming regulatory alignment with the U.S. Food and Drug Administration on the design of the NOV-ERA Phase 2b study of lead candidate ontunisertib, including a novel primary endpoint of endoscopic passability at Week 24 measured by the SES-CD narrowing score. First patients are expected to be dosed in the second half of 2026. The same press release confirmed that topline data from the open-label long-term extension of the STENOVA Phase 2a study in FSCD and from the Phase 1b cohort of AGMB-447 in idiopathic pulmonary fibrosis are due "in the coming months," stacking two binary readouts into a tight catalyst window. Cash and short-term investments of €252 million (roughly $295 million) at June 30, 2026, including $208 million of gross IPO proceeds from February 2026, fund operations into the first half of 2029, the company said.
The thesis is straightforward. AGMB owns two late-Phase-2 assets in fibro-inflammatory indications with no approved pharmacologic therapies, both built around an organ-restricted design that the company believes avoids the systemic toxicity that has historically killed earlier ALK5 inhibitors. The lead asset, ontunisertib, targets fibrostenosing Crohn's disease, a complication of Crohn's disease affecting roughly 46% of the 1.4 million CD patients under treatment across the seven major markets, and for which bowel surgery remains the only durable intervention. AGMB-447, the second asset, targets idiopathic pulmonary fibrosis, a disease with median survival under five years and three approved therapies (Esbriet, Ofev, and the recently approved Jascayd) that slow progression but do not halt it. The market is, in our reading, pricing AGMB primarily as a single-asset FSCD story with optionality on IPF, rather than as a two-program fibro-inflammation platform.
The load-bearing risk is binary and well-defined. A negative or ambiguous NOV-ERA primary endpoint readout in 2027 would, in our view, reset the equity by removing the only direct line of sight to a registrational data set in FSCD, a market with no pharmacological alternative and therefore no obvious next-bid in the equity. The companion risk is mechanistic: ontunisertib's value proposition rests on the assumption that local, gut-restricted ALK5 inhibition can reverse established strictures without systemic TGFβ-driven cardiotoxicity, a hypothesis the Phase 2a data support in principle but that has not yet been validated in a placebo-controlled, dose-ranging study. AGMB-447 carries a related but different exposure: it is inhaled rather than oral, and the IPF efficacy bar set by the two incumbents is high.
The single falsifiable clock is the NOV-ERA first-patient-dosed announcement, which management has guided to the second half of 2026. A clean start with at least one patient enrolled at a Western site before the company's third-quarter trading update, in our view, confirms the operational thesis and removes the largest non-clinical risk overhang. A delay of NOV-ERA into 2027, or a quietly downsized enrollment cap below the planned 320 patients, would be the first warning that the FSCD opportunity is harder to operationalize than the Phase 2a safety readout suggested.